<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02136927</url>
  </required_header>
  <id_info>
    <org_study_id>CLR_12_10</org_study_id>
    <nct_id>NCT02136927</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of SPARC1210 and Reference1210 in Subjects With Metastatic Breast Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharma Advanced Research Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharma Advanced Research Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacokinetic, bioequivalence study
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>Pre-dose, post-dose up to 3 days</time_frame>
    <description>Samples will be collected from all subjects at scheduled time-points: pre-dose and up to 3 days post-dose.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>Day 3</time_frame>
    <description>AEs encountered following dosing with PICN or AbraxaneÂ® will be recorded as per CTCAE, Version 4.0</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>SPARC1210</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous administration of SPARC1210</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference1210</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous administration of Reference1210</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPARC1210</intervention_name>
    <arm_group_label>SPARC1210</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference1210</intervention_name>
    <arm_group_label>Reference1210</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject has given written, informed consent and is available for the entire study.

          -  Histologically or cytologically confirmed diagnosis of breast cancer;

          -  Locally recurrent or metastatic breast cancer for which taxane-based therapy is a
             rational treatment option;

          -  Age 18 years or more

        Exclusion Criteria:

          -  Known hypersensitivity to both the study drugs or its excipients (Cholesteryl sulfate,
             Caprylic acid, Polyvinylpyrrolidone, Ethanol or Polyethylene glycol);

          -  Presence of clinically evident active CNS metastases, including leptomeningial
             involvement, requiring steroid or radiation therapy;

          -  Pre-existing clinically significant peripheral neuropathy (Grade 2 or higher according
             to CTCAE, Version 4.0);

          -  Any other severe concurrent disease which in the judgment of the investigator would
             make the subject inappropriate for entry into this study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SPARC Site 12</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 9</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 6</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 2</name>
      <address>
        <city>Goraj</city>
        <state>Gujarat</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 8</name>
      <address>
        <city>Cochin</city>
        <state>Kerala</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 11</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 5</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 4</name>
      <address>
        <city>Nashik</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 1</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 3</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 10</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 7</name>
      <address>
        <city>Madurai</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2014</study_first_submitted>
  <study_first_submitted_qc>May 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2014</study_first_posted>
  <last_update_submitted>October 20, 2016</last_update_submitted>
  <last_update_submitted_qc>October 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

